Clinical practice in atrial fibrillation (AF) patient management is constantly evolving. In the
past 3 years, various new AF guidelines or focused updates have been published, given this …

Atrial fibrillation (AF) remains a growing problem in the United States and worldwide,
imposing a high individual and health system burden, including increased resource …

The use of warfarin, the most commonly prescribed oral anticoagulant, is being questioned
by clinicians worldwide due to warfarin several limitations (a limited therapeutic window and …

Background Atrial fibrillation (AF) is the most commonly diagnosed arrhythmia, which is
associated with an increased risk of stroke. Several studies have suggested that female AF …

Background: Women with atrial fibrillation are at a higher risk of stroke, despite treatment
with warfarin. It is unclear if women treated with direct oral anticoagulants (DOACs) have …

Making gender bias visible allows to fill the gaps in knowledge and understand health
records and risks of women and men. The coronavirus disease 2019 (COVID-19) pandemic …

Aim Non‐vitamin K antagonist oral anticoagulants (NOACs) are increasingly preferred over
vitamin K antagonists (VKAs) in atrial fibrillation (AF) management. However, differences in …

Abstract Purpose of Review Atrial fibrillation (AF) is the most common sustained cardiac
arrhythmia. The estimated lifetime risk of developing AF is higher in men; however, due to …

Thrombotic and bleeding risks, as well as the incidence and presentation of cardiovascular
events and related outcomes, appear to differ between genders, partly in relation to …

Background Women with atrial fibrillation (AF) experience greater symptomatology, worse
quality of life, and have a higher risk of stroke as compared to men, but are less likely to …